Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system

BACKGROUND: The GLP-1 receptor agonist liraglutide is marketed for obesity treatment where it induces body weight reduction possibly via the hypothalamus, which regulates energy homeostasis. In animal studies, acute liraglutide treatment triggers satiety, weight loss and activates thermogenesis in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaineder, K, Birngruber, T, Rauter, G, Obermüller, B, Eichler, J, Münzker, J, Al-Zoughbi, W, Mautner, S I, Torekov, S S, Hartmann, B, Kotzbeck, P, Pieber, T R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550563/
https://www.ncbi.nlm.nih.gov/pubmed/28507313
http://dx.doi.org/10.1038/ijo.2017.98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550563/
https://www.ncbi.nlm.nih.gov/pubmed/28507313
http://dx.doi.org/10.1038/ijo.2017.98

Ejemplares similares